|Other Names||Cysteine-rich PAK1 inhibitor, CRIPak, CRIPAK|
|Target/Specificity||The synthetic peptide sequence is selected from aa 154-165 of HUMAN CRIPAK|
|Format||Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||Negative regulator of PAK1. It has been suggested that the lost of CRIPAK in breast tumors might contribute to hormonal independence.|
|Cellular Location||Cytoplasm. Membrane. Nucleus Note=Translocated to the nuclear compartment upon hormonal treatment by estrogen|
|Tissue Location||Widely expressed with a highest expression observed in trachea, prostate and adrenal glands. Expressed in many cancer cell lines including breast cancer cells.|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Negative regulator of PAK1. It has been suggested that the lost of CRIPAK in breast tumors might contribute to hormonal independence.
Ota T.,et al.Nat. Genet. 36:40-45(2004).
Talukder A.H.,et al.Oncogene 25:1311-1319(2006).
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.